FDA Proposes Chinese Label Translation Requirement for Sports Supplements

On April 19, 2026, the U.S. Food and Drug Administration (FDA) released a draft guidance titled Dietary Supplement Labeling Guidance Draft, introducing new labeling requirements for sports nutrition supplements sold in the U.S. market with Chinese-language text. The update directly affects importers, manufacturers, and service providers engaged in cross-border trade of protein powders, BCAAs, creatine, and similar products — particularly those targeting bilingual consumers or Chinese-speaking retail channels.

Event Overview

The FDA published the Dietary Supplement Labeling Guidance Draft on April 19, 2026. Section 4.7 of the draft specifies that any sports nutrition dietary supplement bearing Chinese-language ingredient lists, functional claims, or usage instructions must use translations completed by an FDA-registered translation service provider. Such labels must also display a visible ‘FDA-Registered Translation ID’ at the bottom. The public comment period ends on May 20, 2026; the guidance is expected to take effect in Q3 2026.

Industries Affected

Direct Importers and Exporters

Importers placing sports nutrition products into the U.S. market with Chinese labels will face new compliance obligations. Because the requirement applies specifically to Chinese-language content—not just packaging but all label elements including digital inserts or QR-linked instructions—these firms may need to revise label workflows, verify translation vendor status, and retain documentation for FDA review.

Contract Manufacturers and Private-Label Producers

Manufacturers producing private-label or co-packed sports supplements for U.S.-based brands must ensure their clients’ labeling materials—including multilingual versions—comply with the draft rule. This introduces new coordination points between brand owners and production partners regarding language asset management, version control, and regulatory accountability.

Supply Chain Service Providers

Translation agencies, label design firms, and regulatory consultants serving the dietary supplement sector are directly impacted as gatekeepers of compliance. The requirement to use only FDA-registered translation providers creates a new qualification layer—service providers not yet registered may lose eligibility for certain label-related engagements unless they complete registration ahead of implementation.

What Enterprises and Practitioners Should Focus On Now

Monitor official updates through the FDA Docket

The draft remains subject to public comment until May 20, 2026. Stakeholders should track responses in FDA Docket No. FDA-2026-D-XXXXX (to be assigned) for potential revisions to scope, effective date, or exemption criteria — especially regarding minor Chinese annotations (e.g., brand names or non-functional terms).

Identify high-risk product categories and labeling touchpoints

Protein powders, pre-workout formulas, and recovery blends are most likely to include Chinese-language claims or usage instructions. Companies should audit current SKUs for Chinese text across primary packaging, secondary cartons, and digital companion materials — not only printed labels but also e-commerce product pages linked via scannable codes.

Distinguish policy signal from operational mandate

This is a draft guidance, not a binding regulation. While it signals FDA’s enforcement priorities, final requirements may differ in scope or timing. Businesses should avoid full-scale operational overhauls before the final version publishes — instead, prioritize documentation readiness and vendor vetting.

Prepare for translation vendor verification and ID integration

Firms planning to retain Chinese labels should begin identifying FDA-registered translation providers now. They must also assess label real estate constraints: the mandatory ‘FDA-Registered Translation ID’ requires dedicated space at the label bottom — potentially triggering redesigns for compact or multi-language formats.

Editorial Perspective / Industry Observation

From an industry perspective, this draft reflects a broader shift toward traceability and accountability for non-English regulatory communications — especially where consumer-facing claims intersect with safety and substantiation standards. Analysis来看, the requirement is less about restricting Chinese language use and more about establishing an auditable chain of translation responsibility. Observation来看, it functions primarily as a procedural signal rather than an immediate barrier: no new safety thresholds or efficacy standards are introduced, and existing English-language compliance remains unchanged. Current interpretation favors treating this as a supply-chain documentation upgrade — one that aligns with FDA’s increasing emphasis on data integrity across global labeling operations.

Conclusion
While not yet enforceable, the draft guidance marks a formal step toward standardized oversight of multilingual supplement labeling in the U.S. It underscores that language localization is no longer solely a marketing decision — it is increasingly part of the regulatory submission and recordkeeping workflow. For now, the most appropriate understanding is that this is an anticipatory compliance signal: actionable in preparation, but not yet prescriptive in execution.

Information Source
Main source: U.S. FDA, Dietary Supplement Labeling Guidance Draft, published April 19, 2026.
Note: Final version, effective date, and registration process details for translation providers remain pending FDA confirmation and are subject to change following the May 20, 2026 comment deadline.